Journal
JOURNAL OF CELLULAR PHYSIOLOGY
Volume 234, Issue 6, Pages 8286-8294Publisher
WILEY
DOI: 10.1002/jcp.27699
Keywords
cytokine; diabetes mellitus (DM); diabetic complications; diabetic nephropathy (DN); hypoglycemic agents; inflammation; tumor necrosis factor alpha (TNF-alpha)
Categories
Ask authors/readers for more resources
The global prevalence of Type 2 diabetes mellitus and its associated complications are growing rapidly. Although the role of hyperglycemia is well recognized in the pathophysiology of diabetic complications, its exact underlying mechanisms are not fully understood. In this regard, accumulating evidence suggests that the role of inflammation appears pivotal, with studies showing that most diabetic complications are associated with an inflammatory response. Several classes of antidiabetic agents have been introduced for controlling glycemia, with evidence that these pharmacological agents may have modulatory effects on inflammation beyond their glucose-lowering activity. Here we review the latest evidence on the anti-inflammatory effects of commonly used antidiabetic medications and discuss the relevance of these effects on preventing diabetic complications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available